All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-09-17T09:43:17.000Z

SOHO 2019 | Are we ready to use MRD for treatment decisions in patients with MM?

Bookmark this article

During SOHO 2019, Houston, US, the Multiple Myeloma Hub were pleased to host a debate between Thomas G. Martin and Jeffrey L. Wolf, both from the University of California San Francisco, San Francisco, US, on whether we are ready to use MRD for treatment decisions in patients with multiple myeloma (MM).

The interview is a continuation of the debate that started during the session on MM. Concluding, the opponents agree that the definition of MRD needs to be more specific and that, although it may not be ready for prime time use, we are very close.

Are we ready to use MRD for treatment decisions in patients with MM?

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
17 votes - 13 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox